Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CTL Immune Cell Therapy for NSCLC
NCT02766348Phase 2Unknown
- Sponsor
- Shenzhen Hornetcorn Biotechnology Co., Ltd.
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tumor polypeptide pool induced DC-CTL cells in non-small cell lung cancer (NSCLC), sponsored by Shenzhen Hornetcorn Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
tumor polypeptide pool induced DC-CTL cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02766348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766348.